Pillars of growth


Heavy bet for R&D
as a future
growth engine

conocer +


Heavy bet on R&D
as a future
growth engine

find out more

Biosimilar de Enoxaparina


A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.

find out more


Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.

find out more

Fabricación a terceros

Contract manufacturing

High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures


Net profit of the business without R&D in 2018


2018 LMWHglobal sales

56 countries

Bemiparim international presence  with 22 international partners

6 plants

for manufacturing own and third-party products in Spain

€32,4 Mn

of investment in R&D in 2018 Commitment to innovation

7 countries

Direct presence through subsidiaries  to market Enoxaparin

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors


Last news on Rovi 

(See all items)



ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria®

The final results of the pivotal PRISMA-3 study show the efficacy of both dosage strengths of the monthly injectable antipsychotic for the treatment of patients with acute exacerbation of schizophrenia.

Last annual report


Annual Report 2017

Last regular
public information


Executive summary